NCT05574478Completed
Metastatic Breast Cancer-Specific Prognostic Tool
Evaluation of the Acceptability, Appropriateness, Feasibility and Utility of a Metastatic Breast Cancer-Specific Prognostic Tool Among Patients With Metastatic Breast Cancer and Their Caregivers
Source: ClinicalTrials.gov · Last updated 3 Aug 2025
Brief summary (registry, in English)
In this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 20-30 participants). The investigators will code the qualitative data using emerging themes, guided by a well-established implementation science theory, the Consolidated Framework for Implementation Research (CFIR). The information gained from these studies will inform an implementation approach to increase the usability and acceptability of a novel prognostic tool to assist oncologists in the prognosis of patients with metastatic breast cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 19 (actual)
- First submitted
- 6 Oct 2022
- Start date
- 20 Sept 2022
- Primary completion date
- 28 Feb 2024
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Metastatic breast cancer
- NCT number
- NCT05574478
What you commit to
- Study type: Observational
- Participants enrolled: 19
- From 20 Sept 2022 to the primary completion date, 28 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Non-English speaking
- \-
Who the study is looking for
- In order to participate in this study a subject must meet ALL of the eligibility criteria outlined below.
- Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
- Diagnosis of metastatic breast cancer or primary caregiver for someone with a diagnosis of metastatic breast cancer
- Age \> 18 years
- Verbal informed consent obtained to participate in the study.
- Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Terri Eubanks Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.